The pathogenetic and prognostic value of biologic markers in acute lung injury.
Over the past 2 decades, measurement of biomarkers in both the airspaces and plasma early in the course of acute lung injury has provided new insights into the mechanisms of lung injury. In addition, biologic markers of cell-specific injury, acute inflammation, and altered coagulation correlate with mortality from acute lung injury in several single center studies as well as in multicenter clinical trials. To date, biomarkers have been measured largely for research purposes. However, with improved understanding of their role in the pathogenesis of acute lung injury, biomarkers may play an important role in early detection of lung injury, risk stratification for clinical trials, and, ultimately, tailoring specific therapies to individual patients. This article provides a review of biologic markers in acute lung injury, with an emphasis on recent analysis of results from multicenter clinical trials.
Levitt
Joseph E
JE
Division of Pulmonary/Critical Care, Stanford University, Stanford, California 94305, USA. jlevitt@stanford.edu
Gould
Michael K
MK
Ware
Loraine B
LB
Matthay
Michael A
MA
D055371:Acute Lung Injury / Q000209:etiology* / Q000401:mortality* / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis*; D006801:Humans
D015415:Biomarkers